Volitionrx (VNRX) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$2.5M

Revenue (quarter)

$398,657.00

Revenue growth (year over year)

−1.97%

Gross profit (trailing twelve months)

$2.5M

Gross margin

100.00%

Net income (trailing twelve months)

−$25.7M

Net income (quarter)

−$7.3M

Net income growth (year over year)

−15.86%

Net margin

−1046.83%

Return on equity

—

EPS (trailing twelve months)

−$3.85

Book value per share

−$2.67

P/E (trailing twelve months)

—

Price to book

—

Debt to assets

504.04%

Payout ratio

—

Dividend yield

—

Company profile

VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.

• Is Volitionrx (VNRX) profitable?

  No. Volitionrx reported a net loss of $25.7M over the trailing twelve months.

• How much revenue does Volitionrx (VNRX) make?

  Volitionrx generated $2.5M in revenue over the trailing twelve months, down 1.97% year over year.

• How do I buy stock in Volitionrx (VNRX)?

  VNRX trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.